Screening for cryptococcal antigenemia using the lateral flow assay in antiretroviral therapy-naïve HIV-positive adults at an Ethiopian hospital clinic.

Summary, in English

Since treatment for latent cryptococcal infection (CI) before starting antiretroviral therapy (ART) reduces mortality in HIV-infected subjects, screening for cryptococcal antigen (CrAg) in blood is recommended for individuals with CD4 cell counts < 100 cells/µL in regions with high CI prevalence. We assessed CrAg screening using the lateral flow assay in HIV-infected adults eligible for ART in central Ethiopia.

• Author: Anton Reepalu; Taye Balcha; Tadele Yitbarek; Godana Jarso; Erik Sturegård; Per Björkman
• Department/s: Infectious Diseases Research Unit; Clinical Microbiology, Malmö
• Publishing year: 2015
• Language: English
• Publication/Series: BMC Research Notes
• Volume: 8
• Issue: 1
• Links: http://www.ncbi.nlm.nih.gov/pubmed/26597840?dopt=Abstract; http://dx.doi.org/10.1186/s13104-015-1707-6
• Document type: Journal article
• Publisher: BioMed Central (BMC)
• Topic: Infectious Medicine
• Status: Published
• Research group: Infectious Diseases Research Unit; Clinical Microbiology, Malmö
• ISBN/ISSN/Other: ISSN: 1756-0500